GTX-B001
Phase 1Small molecule
GTX-B001 is one of 51 small molecule programs targeting Urticaria. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
50
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
61 competitors in Urticaria
#DrugCompanyPhaseTrials
1Fasenra
AstraZenecaApproved
Clarinex
OOrganon and Co
Approved
Trexall
Alnylam PharmaceuticalsApproved
Neoral
NovartisApproved
Xyzal
CChattem
Approved
Zyrtec
KKenvue Brands
Approved
Pletal
OtsukaApproved
Imuran
LLegacy Health System
Approved
Adrenaline
SSamson Clinical Operations Pty Ltd
Approved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GTX-B001. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- GGranular Therapeutics Limited